Structured evidence table for Phosphatidylserine Focus Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Phosphatidylserine Focus Randomized Trial | Sleep is a complex biological process whose evolutionary purpose has remained equivocal for quite some time.More recently, however, compelling evidence has emerged, leading to recognition of the numerous metabolic and physiological functions sleep contributes to and actively supports. | 4 | Conti Federica (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review |
| Phosphatidylserine Focus Randomized Trial | Epidemiological studies have revealed that sleep deprivation is associated with an increased risk of all-cause mortality,alongside numerous chronic conditions imposing a heavy burden on our healthcare and socioeconomic systems alike,including cardiovascular disease, stroke, obesity, type 2 diabetes, and various types of cancer and neurological disorders. | 4 | Conti Federica (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review |
| Phosphatidylserine Focus Randomized Trial | The scope of this narrative review is to summarize the available evidence on the mechanisms of action and potential benefits of the above-listed nutrients in the context of acute or chronic sleep disturbances. | 4 | Conti Federica (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review |
| Phosphatidylserine Focus Randomized Trial | , , Over the past few decades, there has been an increasing appreciation of the negative impact of sleep disturbances and circadian misalignments on all aspects of human health and performance, ranging from objective alertness, learning, memory, and cognition to emotional regulation, social wellbeing and, most remarkably, physical health. | 4 | Conti Federica (2026) | Dietary Protocols to Promote and Improve Restful Sleep: A Narrative Review |
| Phosphatidylserine Focus Randomized Trial | Given the lack of disease-modifying therapies for dementia, interventions that can stabilize or improve cognition at the MCI stage may substantially reduce future dementia incidence and associated healthcare costs. | 4 | Oh Kang-Il (2026) | Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment |
| Phosphatidylserine Focus Randomized Trial | Because reduced BDNF signaling is closely linked to synaptic dysfunction and memory decline in MCI, we measured BDNF expression in both in vitro and in vivo experiments and assessed downstream ERK/AKT/CREB signaling in the in vivo model. | 4 | Oh Kang-Il (2026) | Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment |
| Phosphatidylserine Focus Randomized Trial | Exposure to 0.3 mM HOfor 24 h markedly reduced cell viability andmRNA levels relative to those in the untreated control group, confirming the successful induction of oxidative cytotoxicity. | 4 | Oh Kang-Il (2026) | Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment |
| Phosphatidylserine Focus Randomized Trial | 1 2 3 4 5 6 Mild cognitive impairment (MCI) refers to more than normal cognitive decline with age, yet insufficient to warrant a diagnosis of dementia []. | 4 | Oh Kang-Il (2026) | Neuroprotective Effect of the Combined Extract of Mentha piperita and Cornus officinalis Against Neuronal Cell Death and Scopolamine-Induced Memory Impairment |
Source documents